Concepts (168)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Poisoning | 5 | 2018 | 32 | 1.220 |
Why?
|
| Registries | 5 | 2018 | 893 | 0.860 |
Why?
|
| Drug Overdose | 6 | 2018 | 131 | 0.740 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 5 | 2018 | 144 | 0.680 |
Why?
|
| Acetaminophen | 4 | 2013 | 58 | 0.640 |
Why?
|
| Analgesics, Non-Narcotic | 3 | 2016 | 35 | 0.620 |
Why?
|
| Referral and Consultation | 4 | 2017 | 423 | 0.490 |
Why?
|
| Toxicology | 4 | 2018 | 33 | 0.420 |
Why?
|
| Drug Hypersensitivity | 1 | 2013 | 28 | 0.390 |
Why?
|
| Analgesics | 1 | 2013 | 102 | 0.370 |
Why?
|
| Hydrocarbons | 1 | 2011 | 9 | 0.360 |
Why?
|
| Inhalation Exposure | 1 | 2011 | 55 | 0.350 |
Why?
|
| Dibenzothiazepines | 1 | 2010 | 7 | 0.340 |
Why?
|
| Cholinergic Antagonists | 1 | 2010 | 32 | 0.340 |
Why?
|
| Barium | 1 | 2009 | 7 | 0.320 |
Why?
|
| Delirium | 1 | 2010 | 53 | 0.320 |
Why?
|
| Hypokalemia | 1 | 2009 | 13 | 0.320 |
Why?
|
| Explosive Agents | 1 | 2009 | 5 | 0.320 |
Why?
|
| Emergency Service, Hospital | 3 | 2013 | 1098 | 0.320 |
Why?
|
| Occupational Exposure | 2 | 2012 | 314 | 0.310 |
Why?
|
| Pneumonia | 1 | 2011 | 291 | 0.290 |
Why?
|
| Antipsychotic Agents | 1 | 2010 | 301 | 0.280 |
Why?
|
| Substance-Related Disorders | 1 | 2014 | 734 | 0.270 |
Why?
|
| Intellectual Disability | 1 | 2009 | 166 | 0.260 |
Why?
|
| Angiotensinogen | 1 | 2023 | 3 | 0.210 |
Why?
|
| Porphyrias, Hepatic | 1 | 2022 | 1 | 0.200 |
Why?
|
| Hyperhomocysteinemia | 1 | 2022 | 6 | 0.200 |
Why?
|
| Male | 14 | 2018 | 29891 | 0.190 |
Why?
|
| Adolescent | 7 | 2017 | 6231 | 0.190 |
Why?
|
| Adult | 11 | 2018 | 16837 | 0.190 |
Why?
|
| Antihypertensive Agents | 1 | 2023 | 169 | 0.190 |
Why?
|
| Middle Aged | 9 | 2018 | 17711 | 0.170 |
Why?
|
| Humans | 22 | 2023 | 63577 | 0.170 |
Why?
|
| Aged | 8 | 2018 | 14465 | 0.160 |
Why?
|
| Female | 11 | 2018 | 32972 | 0.150 |
Why?
|
| Annual Reports as Topic | 1 | 2018 | 1 | 0.150 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 1 | 2018 | 22 | 0.150 |
Why?
|
| Hypertension | 1 | 2023 | 585 | 0.140 |
Why?
|
| Aged, 80 and over | 4 | 2018 | 5464 | 0.140 |
Why?
|
| Gadolinium | 1 | 2018 | 108 | 0.140 |
Why?
|
| Time Factors | 3 | 2017 | 3765 | 0.140 |
Why?
|
| Suicide, Attempted | 3 | 2016 | 107 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2016 | 66 | 0.120 |
Why?
|
| Contrast Media | 1 | 2018 | 425 | 0.120 |
Why?
|
| Infant | 3 | 2016 | 1644 | 0.120 |
Why?
|
| Child | 5 | 2018 | 4519 | 0.120 |
Why?
|
| Monoamine Oxidase Inhibitors | 1 | 2014 | 10 | 0.110 |
Why?
|
| Indans | 1 | 2014 | 12 | 0.110 |
Why?
|
| Antidepressive Agents | 1 | 2016 | 226 | 0.110 |
Why?
|
| Antidepressive Agents, Second-Generation | 1 | 2014 | 30 | 0.110 |
Why?
|
| Drug Interactions | 2 | 2014 | 127 | 0.110 |
Why?
|
| Antidotes | 2 | 2016 | 21 | 0.110 |
Why?
|
| Emergencies | 2 | 2013 | 120 | 0.110 |
Why?
|
| Young Adult | 5 | 2018 | 4695 | 0.100 |
Why?
|
| Hydroquinones | 1 | 2013 | 8 | 0.100 |
Why?
|
| Skin Lightening Preparations | 1 | 2013 | 3 | 0.100 |
Why?
|
| Bleaching Agents | 1 | 2013 | 6 | 0.100 |
Why?
|
| Sodium Hypochlorite | 1 | 2013 | 12 | 0.100 |
Why?
|
| United States | 6 | 2018 | 7846 | 0.100 |
Why?
|
| Status Epilepticus | 1 | 2013 | 24 | 0.100 |
Why?
|
| Child, Preschool | 2 | 2017 | 1989 | 0.100 |
Why?
|
| Parkinson Disease | 1 | 2014 | 131 | 0.100 |
Why?
|
| Renal Insufficiency | 1 | 2013 | 65 | 0.100 |
Why?
|
| Mustard Gas | 1 | 2012 | 6 | 0.090 |
Why?
|
| Chemical Warfare Agents | 1 | 2012 | 4 | 0.090 |
Why?
|
| Vomiting | 2 | 2010 | 137 | 0.090 |
Why?
|
| Blister | 1 | 2012 | 17 | 0.090 |
Why?
|
| Cyclohexylamines | 1 | 2011 | 5 | 0.090 |
Why?
|
| Cyclohexanones | 1 | 2011 | 5 | 0.090 |
Why?
|
| Albuterol | 1 | 2011 | 24 | 0.090 |
Why?
|
| Methylprednisolone | 1 | 2011 | 35 | 0.090 |
Why?
|
| Prednisone | 1 | 2011 | 85 | 0.090 |
Why?
|
| Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 2 | 0.090 |
Why?
|
| Acute Lung Injury | 1 | 2011 | 45 | 0.090 |
Why?
|
| Acute Kidney Injury | 1 | 2013 | 141 | 0.090 |
Why?
|
| Trazodone | 1 | 2010 | 3 | 0.090 |
Why?
|
| Physostigmine | 1 | 2010 | 3 | 0.090 |
Why?
|
| Quetiapine Fumarate | 1 | 2010 | 13 | 0.090 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2010 | 12 | 0.090 |
Why?
|
| Heart Block | 1 | 2010 | 22 | 0.080 |
Why?
|
| Tachycardia | 1 | 2010 | 29 | 0.080 |
Why?
|
| Clonidine | 1 | 2010 | 25 | 0.080 |
Why?
|
| Chemical and Drug Induced Liver Injury | 1 | 2011 | 53 | 0.080 |
Why?
|
| Self Report | 1 | 2013 | 375 | 0.080 |
Why?
|
| Cysteine | 1 | 2011 | 108 | 0.080 |
Why?
|
| Bronchodilator Agents | 1 | 2011 | 119 | 0.080 |
Why?
|
| Kidney | 1 | 2013 | 447 | 0.080 |
Why?
|
| Acetylcysteine | 1 | 2010 | 26 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2014 | 1360 | 0.080 |
Why?
|
| Hypotension | 1 | 2010 | 50 | 0.080 |
Why?
|
| Self-Injurious Behavior | 1 | 2010 | 48 | 0.080 |
Why?
|
| Gastric Lavage | 1 | 2009 | 1 | 0.080 |
Why?
|
| Potassium | 1 | 2009 | 100 | 0.080 |
Why?
|
| Diarrhea | 1 | 2009 | 76 | 0.080 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2009 | 20 | 0.080 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 373 | 0.070 |
Why?
|
| Prevalence | 1 | 2013 | 1383 | 0.070 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2009 | 153 | 0.070 |
Why?
|
| Respiratory Insufficiency | 1 | 2009 | 155 | 0.070 |
Why?
|
| Respiration, Artificial | 1 | 2009 | 297 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2009 | 553 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6668 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2013 | 5696 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2023 | 22 | 0.050 |
Why?
|
| Depression | 1 | 2010 | 900 | 0.050 |
Why?
|
| Injections, Subcutaneous | 1 | 2023 | 69 | 0.050 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 1 | 2023 | 38 | 0.050 |
Why?
|
| Vitamin B 6 | 1 | 2022 | 3 | 0.050 |
Why?
|
| Cystathionine beta-Synthase | 1 | 2022 | 5 | 0.050 |
Why?
|
| Pyridoxine | 1 | 2022 | 3 | 0.050 |
Why?
|
| Sulfur | 1 | 2022 | 15 | 0.050 |
Why?
|
| Heme | 1 | 2022 | 29 | 0.050 |
Why?
|
| Homocysteine | 1 | 2022 | 33 | 0.050 |
Why?
|
| Methionine | 1 | 2022 | 55 | 0.050 |
Why?
|
| Folic Acid | 1 | 2022 | 41 | 0.050 |
Why?
|
| Injections, Intravenous | 2 | 2013 | 156 | 0.050 |
Why?
|
| Double-Blind Method | 1 | 2023 | 741 | 0.040 |
Why?
|
| Blood Pressure | 1 | 2023 | 510 | 0.040 |
Why?
|
| Prognosis | 2 | 2017 | 1746 | 0.040 |
Why?
|
| RNA Interference | 1 | 2023 | 617 | 0.040 |
Why?
|
| Diet | 1 | 2023 | 527 | 0.040 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 455 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2011 | 862 | 0.040 |
Why?
|
| Weapons of Mass Destruction | 1 | 2018 | 2 | 0.040 |
Why?
|
| Demography | 1 | 2018 | 173 | 0.040 |
Why?
|
| Israel | 1 | 2017 | 26 | 0.030 |
Why?
|
| Pharmaceutical Preparations | 1 | 2018 | 123 | 0.030 |
Why?
|
| Toxiferine | 1 | 2016 | 1 | 0.030 |
Why?
|
| Sentinel Surveillance | 1 | 2016 | 19 | 0.030 |
Why?
|
| Societies, Scientific | 1 | 2016 | 36 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2022 | 919 | 0.030 |
Why?
|
| Pediatrics | 1 | 2018 | 255 | 0.030 |
Why?
|
| Research Personnel | 1 | 2016 | 94 | 0.030 |
Why?
|
| Program Evaluation | 1 | 2017 | 487 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2017 | 873 | 0.030 |
Why?
|
| Lorazepam | 1 | 2013 | 8 | 0.030 |
Why?
|
| Phenobarbital | 1 | 2013 | 12 | 0.030 |
Why?
|
| Phenytoin | 1 | 2013 | 16 | 0.030 |
Why?
|
| Ataxia | 1 | 2013 | 23 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2013 | 47 | 0.020 |
Why?
|
| Anticonvulsants | 1 | 2013 | 104 | 0.020 |
Why?
|
| Eating | 1 | 2013 | 138 | 0.020 |
Why?
|
| Poison Control Centers | 1 | 2012 | 6 | 0.020 |
Why?
|
| Fisheries | 1 | 2012 | 2 | 0.020 |
Why?
|
| Seizures | 1 | 2013 | 142 | 0.020 |
Why?
|
| Renal Dialysis | 1 | 2013 | 196 | 0.020 |
Why?
|
| Hospitals, Community | 1 | 2012 | 71 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2013 | 288 | 0.020 |
Why?
|
| Arabia | 1 | 2011 | 1 | 0.020 |
Why?
|
| New England | 1 | 2012 | 273 | 0.020 |
Why?
|
| Intubation, Intratracheal | 1 | 2013 | 203 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 21 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 2010 | 39 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2010 | 173 | 0.020 |
Why?
|
| Safety | 1 | 2010 | 145 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2011 | 465 | 0.020 |
Why?
|
| Nausea | 1 | 2010 | 111 | 0.020 |
Why?
|
| Drug Storage | 1 | 2009 | 22 | 0.020 |
Why?
|
| Skin | 1 | 2012 | 374 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2018 | 2253 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2569 | 0.020 |
Why?
|
| Alcohol Drinking | 1 | 2011 | 315 | 0.020 |
Why?
|
| Internet | 1 | 2011 | 466 | 0.020 |
Why?
|
| Drug Utilization | 1 | 2009 | 208 | 0.020 |
Why?
|
| Alcoholism | 1 | 2011 | 318 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2009 | 462 | 0.020 |
Why?
|
| Biomarkers | 1 | 2011 | 1407 | 0.010 |
Why?
|
| Risk Factors | 1 | 2011 | 5353 | 0.010 |
Why?
|